| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
3 companies
Mitchell Dean J serves as a Director at PGEN and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 4 buys and 0 sells. Those positions are worth an estimated $10.8M at current prices.
Historically, Mitchell Dean J's trades have earned a below-average insider score of 45/100 across 3 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of +9.1%.
The biggest single holding is PRAX (~$5.7M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 75,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2023 | PGEN Precigen, Inc. | Director | Buy | 25,000 | $1.41 | $35,250.00 | +7.5% | -19.3% | -28.9% | |
| Mar 24, 2023 | PRAX Praxis Precision Medicines, Inc. | Director | Buy | 50,000 | $0.84 | $41,815.00 | +200.0% | +40.7% | +339.5% | |
| Jun 8, 2022 | PRAX Praxis Precision Medicines, Inc. | Director | Buy | 25,000 | $1.81 | $45,187.50 | New | +61.1% | -43.9% | |
| Aug 11, 2017 | PGEN Precigen, Inc. | Director | Buy | 5,000 | $18.33 | $91,639.50 | +38.2% | - | - |